Duchenne muscular dystrophy: Focus on pharmaceutical and nutritional interventions

International Journal of Biochemistry and Cell Biology

Volumn 39, Issue 3, 2007, Pages 469-477

  Radley, H G ^a   De Luca, A ^b   Lynch, G S ^c   Grounds, M D ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF BARI   (Italy)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Duchenne muscular dystrophy; Mdx mouse; Nutritional supplements; Pharmaceuticals; Therapy

Indexed keywords

AMINO ACID; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BN 82270; CALPASTATIN; CARNITINE; CARNITINE PLUS LEUPEPTIN; CORTICOSTEROID; CREATINE; CROMOGLYCATE DISODIUM; CYCLOSPORIN; DEFLAZACORT; DYSTROPHIN; EPIGALLOCATECHIN GALLATE; ETANERCEPT; FORMOTEROL; GREEN TEA EXTRACT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; ION CHANNEL; LEUPEPTIN; MYODUR; OXATOMIDE; PENTOXIFYLLINE; PREDNISONE; SALBUTAMOL; STEROID; TUMOR NECROSIS FACTOR ALPHA; UBIDECARENONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

APPETITE; CATARACT; CLINICAL TRIAL; CONNECTIVE TISSUE; DEATH; DIET SUPPLEMENTATION; DRUG TARGETING; DUCHENNE MUSCULAR DYSTROPHY; EVALUATION; GROWTH RETARDATION; HEART RATE; HUMAN; MEDICAL RESEARCH; MUSCLE ATROPHY; MUSCLE DISEASE; MUSCLE FIBER MEMBRANE; MUSCLE NECROSIS; NONHUMAN; PROTEIN DEFECT; RESPIRATORY FAILURE; SHORT STATURE; SHORT SURVEY; SIDE EFFECT; SKELETAL MUSCLE; TREATMENT OUTCOME; TREATMENT PLANNING; TREMOR; WEIGHT GAIN; X CHROMOSOME LINKED DISORDER;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ANIMALS; ANTI-INFLAMMATORY AGENTS; CYTOKINES; DIETARY SUPPLEMENTS; HUMANS; ION CHANNELS; MICE; MICE, INBRED MDX; MUSCULAR DYSTROPHY, ANIMAL; MUSCULAR DYSTROPHY, DUCHENNE; PROTEASE INHIBITORS;

EID: 33846194248     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2006.09.009     Document Type: Short Survey

References (44)

1. Archer J.D., Vargas C.C., and Anderson J.E. Persistent and improved functional gain in mdx dystrophic mice after treatment with l-arginine and Deflazacort. The FASEB Journal 20 6 (2006) 738-740
2. Biggar W.D. Duchenne muscular dystrophy. Pediatrics in Review 27 3 (2006) 83-88
3. Birdsall T. Therapeutic applications of taurine. Altitude Medicine Review 3 2 (1998) 128-136
4. Buetler T.M., Renard M., Offord E.A., Schneider H., and Ruegg U.T. Green tea extract decreases muscle necrosis in mdx mice and protects against reactive oxygen species. American Journal of Clinical Nutrition 75 4 (2002) 749-753
5. Burdi R., Didonna M.P., Pignol B., Nico B., Mangieri D., Rolland J.F., et al. First evaluation of the potential effectiveness in muscular dystrophy of a novel chimeric compound, BN 82270, acting as calpain-inhibitor and anti-oxidant. Neuromuscular Disorders 16 4 (2006) 237-248
6. Chen S.-S. Administration of Chinese herbal medicines facilitates the locomotor activity in dystrophin-deficient mice. American Journal of Chinese Medicine: Administration of Chinese Herbal Medicines 29 2 (2001) 281-292
7. Conte Camerino D., Tricarico D., Pierno S., Desaphy J.F., Liantonio A., Pusch M., et al. Taurine and skeletal muscle disorders. Neurochemical Research 29 1 (2004) 135-142
8. Courdier-Fruh I., Barman L., Wettstein P., and Meier T. Detection of glucocorticoid-like activity in traditional Chinese medicine used for the treatment of Duchenne muscular dystrophy. Neuromusculcular Disorders 13 9 (2003) 699-704
9. De Luca A., Nico B., Liantonio A., Didonna M.P., Fraysse B., Pierno S., et al. A multidisciplinary evaluation of the effectiveness of cyclosporine a in dystrophic mdx mice. American Journal of Pathology 166 2 (2005) 477-489
10. De Luca A., Pierno S., Liantonio A., Cetrone M., Camerino C., Fraysse B., et al. Enhanced dystrophic progression in mdx mice by exercise and beneficial effects of taurine and insulin-like growth factor-1. Journal of Pharmacological and Experimental Therapeutics 304 1 (2003) 453-463
11. Dorchies O.K., Wagner S., Vuadens O., Waldhauser K., Buetler T.M., Kucera P., et al. Green tea extract and its major polyphenol (-)-epigallocatechin gallate improve muscle function in a mouse model for Duchenne muscular dystrophy. American Journal of Cell Physiology 290 (2006) C616-C625
12. Dupont-Versteegden E.E., Katz M.S., and McCarter R.J. Beneficial versus adverse effects of long-term use of clenbuterol in mdx mice. Muscle & Nerve 18 (1995) 1447-1459
13. Escolar D.M., Buyse G., Henricson E., Leshner R., Florence J., Mayhew J., et al. CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy. Annals of Neurology 58 1 (2005) 151-155
14. Feldman M., and Maini R.N. Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nature Medicine 9 (2003) 1245-1250
15. Fowler E.G., Graves M.C., Wetzel G.T., and Spencer M.J. Pilot trial of albuterol in Duchenne and Becker muscular dystrophy. Neurology 62 6 (2004) 1006-1008
16. Gosselin L.E., and Williams J.E. Pentoxifylline fails to attenuate fibrosis in dystrophic (mdx) diaphragm muscle. Muscle Nerve 33 6 (2006) 820-823
17. Granchelli J.A., Avosso D.L., Hudecki M.S., and Pollina C. Cromolyn increases strength in exercised mdx mice. Research Communications in Molecular Pathology and Pharmacology 91 3 (1996) 287-296
18. Granchelli J.A., Pollina C., and Hudecki M.S. Pre-clinical screening of drugs using the mdx mouse. Neuromusclular Disorders 10 (2000) 235-239
19. Grounds M.D., and Torrisi J. Anti-TNFα (Remicade) therapy protects dystrophic skeletal muscle from necrosis. The FASEB Journal 18 (2004) 676-682
20. Harcourt, L. J., Schertzer, J. D., Ryall, J. G., & Lynch, G. S. (2006). Low dose formoterol administration improves muscle function in dystrophic mdx mice without increasing fatigue. Neuromuscular Disorders, in press.
21. Hodgetts S.I., Radley H.G., Davies M., and Grounds M.D. Reduced necrosis of dystrophic muscle by depletion of host neutrophils, or blocking TNFalpha function with Etanercept in mdx mice. Neuromuscular Disorders 16 9-10 (2006) 591-602
22. Hsu C.C., Ho M.C., Lin L.C., Su B., and Hsu M.C. American ginseng supplementation attenuates creatine kinase level induced by submaximal exercise in human beings. World Journal of Gastroenterology 11 34 (2005) 5327-5331
23. Lynch G.S., Hinkle R.T., and Faulkner J.A. Power output of fast and slow skeletal muscles of mdx (dystrophic) and control mice after clenbuterol treatment. Experimental Physiology 85 3 (2000) 295-299
24. Marques M.J., Luz M.A., Minatel E., and Neto H.S. Muscle regeneration in dystrophic mdx mice is enhanced by isosorbide dinitrate. Neuroscience Letters 382 3 (2005) 342-345
25. McGeachie J.K., Grounds M.D., Partridge T.A., and Morgan J.E. Age-related changes in replication of myogenic cells in mdx mice: Quantitative autoradiographic studies. Journal of Neurological. Sciences 119 (1993) 169-179
26. Mok E., Eleouet-Da Violante C., Daubrosse C., Gottrand F., Rigal O., Fontan J.E., et al. Oral glutamine and amino acid supplementation inhibit whole-body protein degradation in children with Duchenne muscular dystrophy. American Journal of Clinical Nutrition 83 4 (2006) 823-828
27. Passaquin C.-C., Renard M., Kay L., Challet C., Mokhtarian A., Wallimann T., et al. Creatine supplementation reduces skeletal muscle degeneration and enhances mitochondrial function in mdx mice. Neuromuscular Disorders 12 (2002) 174-182
28. Payne E.T., Yasuda N., Bourgeois J.M., Devries M.C., Rodriguez M.C., Yousuf J., et al. Nutritional therapy improves function and complements corticosteroid intervention in mdx mice. Muscle Nerve 33 1 (2006) 66-77
29. Pearlman J.P., and Fielding R.A. Creatine monohydrate as a therapeutic aid in muscular dystrophy. Nutrition Review 64 2 Pt. 1 (2006) 80-88
30. Pierno, S., Nico, B., Burdi, R., Liantonio, A., Didonna, M. P., Cippone, V., et al. (2006). Role of TNF-a, but not of COX-2 derived eicosanoids, on functional and morphological indexes of dystrophic progression in mdx mice: A pharmacological approach. Neuropathology and Applied Neurobiology, in press.
31. Radley H.G., and Grounds M.D. Cromolyn administration (to block mast cell degranulation) reduces necrosis of dystrophic muscle in mdx mice. Neurobiology of Disease 23 2 (2006) 387-397
32. Rando T.A. Oxidative stress and the pathogenesis of muscular dystrophies. American Journal of Physical Medicine & Rehabilitation 81 11 Suppl. (2002) S175-S186
33. Rolland, J. F., De Luca, A., Burdi, R., Andreetta, F., Confalonieri, P., & Conte Camerino, D. (2006). Overactivity of exercise-sensitive cation channels and their impaired modulation by IGF-1 in mdx native muscle fibers: Beneficial effect of pentoxifylline. Neurobiology of Disease, in press [Epub ahead of print].
34. Ryall J.G., Sillence M.N., and Lynch G.S. Systemic administration of beta2-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses. British Journal of Pharmacology 147 6 (2006) 587-595
35. Sharma K.R., Mynhier M.A., and Miller R.G. Cyclosporine increases muscular force generation in Duchenne muscular dystrophy. Neurology 43 3 Pt. 1 (1993) 527-532
36. Spencer M.J., Croall D.E., and Tidball J.G. Calpains are activated in necrotic fibers from mdx dystrophic mice. Journal of Biological Chemistry 270 (1995) 10909-10914
37. Stedman H.H., Sweeny H.L., Shrager J.B., Maguire H.C., Panettieri R.A., Petrof B., et al. The MDX mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature 352 August (1991) 536-538
38. Tarnopolsky M.A., Mahoney D.J., Vajsar J., Rodriguez C., Doherty T.J., Roy B.D., et al. Creatine monohydrate enhances strength and body composition in Duchenne muscular dystrophy. Neurology 62 10 (2004) 1771-1777
39. Tidball J.G. Inflammatory processes in muscle injury and repair. American Journal of Physiology-Regulatory Integrative and Comparative Physiology 288 2 (2005) R345-R353
40. Tidball J.G., and Wehling-Henricks M. Damage and inflammation in muscular dystrophy: Potential implications and relationships with autoimmune myositis. Current Opinion in Rheumatology 17 (2005) 707-713
41. Urtizberea J.A., Fan Q.S., Vroom E., Recan D., and Kaplan J.C. Looking under every rock: Duchenne muscular dystrophy and traditional Chinese medicine. Neuromuscular Disorders 13 9 (2003) 705-707
42. Vary T., Dardevet D., Grizard J., Voisin L., Buffiere C., Denis P., et al. Pentoxifylline improves insulin action limiting skeletal muscle catabolism after infection. Journal of Endocrinology 163 1 (1999) 15-24
43. Voisin V., et al. l-Arginine improves dystrophic phenotype in mdx mice. Neurobiology of Disease 20 (2005) 123-130
44. Whitehead N.P., Yeung E.W., and Allen D.G. Muscle damage in mdx (dystrophic) mice: Role of calcium and reactive oxygen species. Clinical & Experimental Pharmacology and Physiology 33 (2006) 657-662